Clinigen Group (LON:CLIN) released its quarterly earnings data on Tuesday. The company reported GBX 21.20 ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 20.30 ($0.28) by GBX 0.90 ($0.01), Bloomberg Earnings reports. Clinigen Group had a net margin of 0.70% and a return on equity of 0.98%. The firm had revenue of £1,678 billion during the quarter.
Clinigen Group (CLIN) opened at GBX 1,016 ($14.04) on Tuesday. The firm has a market cap of $1,260.00 and a PE ratio of 33,866.67. Clinigen Group has a 12 month low of GBX 751.50 ($10.38) and a 12 month high of GBX 1,187 ($16.40).
Several research firms recently issued reports on CLIN. Berenberg Bank began coverage on shares of Clinigen Group in a research report on Wednesday, November 1st. They set a “hold” rating and a GBX 1,200 ($16.58) price objective for the company. Peel Hunt reaffirmed a “buy” rating and set a GBX 1,350 ($18.65) target price on shares of Clinigen Group in a research note on Tuesday, October 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a GBX 1,360 ($18.79) target price on shares of Clinigen Group in a research note on Tuesday, November 7th. N+1 Singer reaffirmed a “buy” rating and set a GBX 1,225 ($16.92) target price on shares of Clinigen Group in a research note on Wednesday, November 29th. Finally, Numis Securities reaffirmed an “add” rating and set a GBX 1,208 ($16.69) target price on shares of Clinigen Group in a research note on Tuesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of GBX 1,222.17 ($16.89).
ILLEGAL ACTIVITY NOTICE: “Clinigen Group (CLIN) Announces Quarterly Earnings Results, Beats Expectations By $0.90 EPS” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3225333/clinigen-group-clin-announces-quarterly-earnings-results-beats-expectations-by-0-90-eps.html.
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.